These findings establish EDNRB-mediated anoikis regulation as a key mechanism in IPF and urgently warrant clinical trials to validate endothelin receptor antagonists for targeted anti-fibrotic therapy. Here, EDNRB is linked to idiopathic pulmonary fibrosis.